Page last updated: 2024-11-05

sulisobenzone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Sulisobenzone is an organic compound that acts as a UV filter. It is primarily used in sunscreen products. The compound is a benzophenone derivative and is synthesized through a series of chemical reactions involving starting materials like benzophenone and an appropriate sulfonic acid derivative. Sulisobenzone is particularly effective at absorbing UVB rays, which are known to cause sunburn and skin damage. Researchers study sulisobenzone to understand its effectiveness and safety in sunscreen formulations, as well as its potential environmental impacts. '

Cross-References

ID SourceID
PubMed CID19988
CHEMBL ID2059073
CHEBI ID135312
SCHEMBL ID16330
MeSH IDM0053995

Synonyms (123)

Synonym
nsc-60584
AC-19869
CBMICRO_016354
nsc654266
brn 2889165
uvinul ms-40 substanz
2-hydroxy-4-methoxybenzophenone-5-sulfonic acid
uvinul ms 40
hsdb 7422
uvinuc ms 40
einecs 223-772-2
sulisobenzonum [inn-latin]
benzophenone-4
5-benzoyl-4-hydroxy-2-methoxybenzolsulfonsaeure
syntase 230
sulisobenzona [inn-spanish]
sungard
benzophenone 4
5-benzoyl-4-hydroxy-2-methoxybenzene sulfonic acid
ms 40
seesorb 101s
sulisobenzonum
sulisobenzona
uval
spectra-sorb uv 284
sungard (tn)
sulisobenzone (usp/inn)
D05964
4065-45-6
5-benzoyl-4-hydroxy-2-methoxybenzenesulfonic acid ammoniate
uval sodium salt
uvinul ms 40 sodium salt
sulisobenzone ,
uval (*sodium salt*)
1-phenol-4-sulfonic acid, 2-benzoyl-5-methoxy-
benzenesulfonic acid, 5-benzoyl-4-hydroxy-2-methoxy-
cyasorb uv 284 (*sodium salt*)
nsc60584
uvinul ms 40 (*sodium salt*)
5-benzoyl-4-hydroxy-2-methoxybenzenesulfonic acid
cyasorb uv 284 sodium salt
5-benzoyl-4-hydroxy-2-methoxy-benzenesulfonic acid
benzenesulfonic acid, 5-benzoyl-4-hydroxy-2-methoxy-, sodium salt
sulisobenzone (usan) (*sodium salt*)
1-phenol-4-sulfonic acid, 2-benzoyl-5-methoxy-, sodium salt
NCGC00159404-02
NCGC00159404-03
CHEBI:135312
2-hydroxy-4-methoxy-5-sulfobenzophenone
H0466
NCGC00159404-04
NCGC00159404-05
4-hydroxy-2-methoxy-5-(phenylcarbonyl)benzenesulfonic acid
2-hydroxy-4-methoxy-5-sulfonylbenzophenone(bp-4)
dtxcid0022436
tox21_303469
cas-4065-45-6
NCGC00257488-01
dtxsid2042436 ,
tox21_111639
tox21_202332
NCGC00259881-01
A825218
nsc-760350
bp-4 benzophenone
smr001262265
MLS004734662
uvinul d 5030
uvinul ms-40
viosorb 111
uvasorb s 5
sulfisobenzone
CHEMBL2059073
escalol 577
S4652
1w6l629b4k ,
unii-1w6l629b4k
ec 223-772-2
sulisobenzone [usan:usp:inn]
FT-0612547
sulisobenzone [who-dd]
2-benzoyl-5-methoxy-1-phenol-4-sulfonic acid
sulisobenzone [usp monograph]
sulisobenzone [hsdb]
sulisobenzone [usan]
sulisobenzone [usp-rs]
sulfisobenzone [vandf]
benzophenone-4 [inci]
sulisobenzone [mart.]
sulisobenzone [mi]
3-benzoyl-4-hydroxy-6-methoxybenzenesulfonic acid
sulisobenzone [inn]
AKOS015895600
hmbs
uvinul ms40
4-hydroxy-2-methoxy-5-(oxo-phenylmethyl)benzenesulfonic acid
SCHEMBL16330
tox21_111639_1
CS-4610
spectra-sorb u.v. 284
cyasorb uv 284 (salt/mix)
HY-B1162
5-benzoyl-4-hydroxy-2-methoxy-besylic acid
mfcd00024962
J-509633
sulisobenzone, analytical standard
5-benzoyl-4-hydroxy-2-methoxybenzenesulfonic acid, >=97.0% (hplc)
sulisobenzone, united states pharmacopeia (usp) reference standard
DB11185
SY036839
F11240
2-benzoyl-5-methoxy-1-phenol-4-sulphonic acid
AS-12605
Q7636301
CCG-267557
sulisobenzone (mart.)
sulisobenzona (inn-spanish)
sulisobenzone (usp monograph)
anti-frizz sheets
sulisobenzone (usp-rs)
3-benzoyl-4-hydroxy-6-methoxybenesulfonic acid
sulisobenzonum (inn-latin)
sulisobenzone (usan:usp:inn)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Sunscreens are widely utilized due to the adverse effects of ultraviolet (UV) radiation on human health."( Altered UV absorbance and cytotoxicity of chlorinated sunscreen agents.
Kennedy, S; Purser, GH; Sheaff, RJ; Sherwood, VF; Zhang, H, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Le dosage a été validé en termes de spécificité, de linéarité, d’exactitude et de précision intra- et inter-journalières, de limites de détection et de limites de quantification."( A simple and reliable isocratic high-performance chromatographic assay for the simultaneous determination of hydrophilic benzophenone-4 and lipophilic octocrylene in sunscreens.
Pan, P; Svirskis, D; Waterhouse, GIN; Wu, Z, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzophenonesAny aromatic ketone in which the carbonyl group is bonded to 2 phenyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency17.03640.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency1.38670.000714.592883.7951AID1259369
Microtubule-associated protein tauHomo sapiens (human)Potency6.35150.180013.557439.8107AID1460; AID1468
AR proteinHomo sapiens (human)Potency29.84930.000221.22318,912.5098AID743040
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency12.58930.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency48.33360.001022.650876.6163AID1224838; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency9.52050.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency43.84990.003041.611522,387.1992AID1159552
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency16.32790.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency0.68420.375827.485161.6524AID743217
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency48.43950.001019.414170.9645AID743191
activating transcription factor 6Homo sapiens (human)Potency55.70820.143427.612159.8106AID1159516
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency79.43280.010323.856763.0957AID2662
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency40.53340.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency0.02240.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID673449Inhibition of recombinant phosphatase activity of Cdc25B catalytic domain expressed in Escherichia coli BL21(DE3) using OMFP as substrate at 50 uM by spectrofluorimetric analysis2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Discovery of new inhibitors of Cdc25B dual specificity phosphatases by structure-based virtual screening.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (58)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (3.45)18.7374
1990's3 (5.17)18.2507
2000's4 (6.90)29.6817
2010's34 (58.62)24.3611
2020's15 (25.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.42 (24.57)
Research Supply Index4.13 (2.92)
Research Growth Index5.77 (4.65)
Search Engine Demand Index47.56 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies3 (5.00%)4.05%
Observational0 (0.00%)0.25%
Other56 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]